RxDoctor Payments Data

Haley Duncan

Psychiatric/Mental Health · Sylacauga, ALNPI 1285300590

Payments from drug & device makers

$2,253in general payments, 2019–2025

Across 43 payments — averaging $52.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$572
  • Neurocrine Biosciences, Inc.$415
  • Otsuka America Pharmaceutical, Inc.$404
  • Vanda Pharmaceuticals Inc.$250
  • AbbVie$210
  • E.r. Squibb & Sons, L.L.C.$122
  • plus $280 from 6 others

What the payments were for

  • Food & beverage$2,253100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,253 in reported general payments places this provider in the 65th percentile of 378 psychiatric/mental health providers in Alabama.

See all psychiatric/mental health providers in Alabama

Medicare billing

Part B allowed, 2024
$3,080
Medicare patients
28
Services billed
61

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate38$125,922
Abilify MaintenaAripiprazole14$40,055
Clozapine26$2,016
Fluphenazine Hcl14$1,817
Fluphenazine Decanoate14$1,309
Aripiprazole29$1,093
Trazodone Hcl78$891
Benztropine Mesylate64$883
Olanzapine40$836
Hydroxyzine Pamoate40$702
Haloperidol Decanoate21$617
Quetiapine Fumarate48$520
Divalproex Sodium26$473
Hydroxyzine Hcl28$469
Haloperidol12$415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$120$125,92238 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$404$40,05514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 378 psychiatric/mental health providers in Alabama.

Other psychiatric/mental health in Sylacauga

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →